eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2023
vol. 40
 
Share:
Share:
abstract:
Original paper

Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites

Agnieszka Bogacz-Piaseczyńska
1
,
Andrzej Bożek
1
,
Maciej Pastuszczak
1
,
Jolanta Zalejska-Fiolka
2

  1. Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland
  2. Department of Biochemistry, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland
Adv Dermatol Allergol 2023; XL (4): 542-547
Online publish date: 2023/07/14
View full text Get citation
 
Introduction:
Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD).

Aim:
To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens.

Material and methods:
In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months’ AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed.

Results:
Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (p < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT.

Conclusions:
HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT.

keywords:

immunoglobulin E, mites, atopic dermatitis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.